494
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Effects of human recombinant-interferon β in experimental autoimmune encephalomyelitis in guinea pigs

, , , , , & show all
Pages 1273-1279 | Received 22 Dec 2009, Accepted 10 Mar 2010, Published online: 26 Aug 2010

Figures & data

Figure 1. Effect of IFN beta-1b on mitogen-induced proliferation of peripheral blood mononuclear cells of guinea pigs (A), rabbits (B) and rats (C). The mononuclear cells were treated with 10 μg/ml PHA (Figures A and B) or 3 μg/ml Con A (Figure B) for 72 h. The cell proliferation was assessed by [3H]-TdR uptake. Cells were pulsed with [3H]-TdR 24 h before harvesting. Results represent means ± SD (n = 5). Statistical analysis was made according to Dunnett’s test; significant difference was noted in the figures at p <0.05.

Figure 1.  Effect of IFN beta-1b on mitogen-induced proliferation of peripheral blood mononuclear cells of guinea pigs (A), rabbits (B) and rats (C). The mononuclear cells were treated with 10 μg/ml PHA (Figures A and B) or 3 μg/ml Con A (Figure B) for 72 h. The cell proliferation was assessed by [3H]-TdR uptake. Cells were pulsed with [3H]-TdR 24 h before harvesting. Results represent means ± SD (n = 5). Statistical analysis was made according to Dunnett’s test; significant difference was noted in the figures at p <0.05.

Figure 2. Changes in 2′,5′-oligoadenylate synthetase (2-5 AS) activity of peripheral blood after treatment of animals with Betaferon. Betaferon or IFN-β1b was given subcutaneously into the abdomen of the animals. The 2-5AS activity of peripheral blood samples was determined at 0, 24, 48 and 96 h after Betaferon injection. Each point represents the mean ± SD of four animals. *Significantly different from pre-values at the time 0, p <0.05; **p <0.01; ***p <0.001 (paired t-test).

Figure 2.  Changes in 2′,5′-oligoadenylate synthetase (2-5 AS) activity of peripheral blood after treatment of animals with Betaferon. Betaferon or IFN-β1b was given subcutaneously into the abdomen of the animals. The 2-5AS activity of peripheral blood samples was determined at 0, 24, 48 and 96 h after Betaferon injection. Each point represents the mean ± SD of four animals. *Significantly different from pre-values at the time 0, p <0.05; **p <0.01; ***p <0.001 (paired t-test).

Figure 3. Inhibitory effects of Betaferon on neurological deficits of guinea pigs that were immunized with porcine myelin basic protein (MBP). Vehicle (——) or GPA-Betaferon at 1.2 MIU/kg (- - -) or 12 MIU/kg (- — -) was administered subcutaneously daily for 20 days. The mean of the daily clinical scores for each group of 10 animals is shown. See for the statistical analysis.

Figure 3.  Inhibitory effects of Betaferon on neurological deficits of guinea pigs that were immunized with porcine myelin basic protein (MBP). Vehicle (——) or GPA-Betaferon at 1.2 MIU/kg (- - -) or 12 MIU/kg (- — -) was administered subcutaneously daily for 20 days. The mean of the daily clinical scores for each group of 10 animals is shown. See Table 1 for the statistical analysis.

Table 1. Cumulative clinical scores of EAE guinea pigs after repeated subcutaneous administration of GPA-Betaferon.

Figure 4. Effects of GPA-Betaferon on body weight in guinea pigs sensitized with porcine myelin basic protein (P-MBP). Vehicle (•) or GPA-Betaferon at 1.2 MIU/kg (○) or 12 MIU/kg (□) was administered subcutaneously daily for 20 days. Each value represents the mean ± SD, and figures in parentheses indicate the number of surviving animals.

Figure 4.  Effects of GPA-Betaferon on body weight in guinea pigs sensitized with porcine myelin basic protein (P-MBP). Vehicle (•) or GPA-Betaferon at 1.2 MIU/kg (○) or 12 MIU/kg (□) was administered subcutaneously daily for 20 days. Each value represents the mean ± SD, and figures in parentheses indicate the number of surviving animals.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.